Gubra A/S (GUBRA.CO)

DKK 728.0

(2.82%)

Net Debt Summary of Gubra A/S

Gubra A/S's latest annual net debt in 2023 was 18.03 Million DKK , up 815.23% from previous year.
Gubra A/S's latest quarterly net debt in 2024 Q1 was -46.9 Million DKK , down -360.03% from previous quarter.
Gubra A/S reported annual net debt of -2.52 Million DKK in 2022, up 96.02% from previous year.
Gubra A/S reported annual net debt of -63.34 Million DKK in 2021, down -641.3% from previous year.
Gubra A/S reported quarterly net debt of -46.9 Million DKK for 2024 Q2, up 194.99% from previous quarter.
Gubra A/S reported quarterly net debt of 18.03 Million DKK for 2023 FY, up 815.23% from previous quarter.

Annual Net Debt Chart of Gubra A/S (2023 - 2019)

Historical Annual Net Debt of Gubra A/S (2023 - 2019)

Year	Net Debt	Net Debt Growth
2023	18.03 Million DKK	815.23%
2022	-2.52 Million DKK	96.02%
2021	-63.34 Million DKK	-641.3%
2020	-8.54 Million DKK	-150.13%
2019	17.04 Million DKK	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-46.9 Million DKK	-360.03%
2024 Q2	-46.9 Million DKK	194.99%
2023 FY	18.03 Million DKK	815.23%
2023 Q3	7.28 Million DKK	179.18%
2023 Q2	-9.2 Million DKK	45.66%
2023 Q4	18.03 Million DKK	147.5%
2023 Q1	-16.93 Million DKK	-571.65%
2022 Q4	-2.52 Million DKK	77.0%
2022 FY	-2.52 Million DKK	96.02%
2022 Q3	-10.96 Million DKK	0.0%
2022 Q1	115.78 Million DKK	0.0%
2021 FY	-63.34 Million DKK	-641.3%
2020 FY	-8.54 Million DKK	-150.13%
2019 FY	17.04 Million DKK	0.0%

Peer Net Debt Comparison of Gubra A/S

Name	Net Debt	Net Debt Difference
ALK-Abelló A/S	291 Million DKK	93.801%
Bavarian Nordic A/S	-1.33 Billion DKK	101.354%
Genmab A/S	-14.09 Billion DKK	100.128%
Novo Nordisk A/S	12.61 Billion DKK	99.857%
Orphazyme A/S	-11.26 Million DKK	260.067%
Pharma Equity Group A/S	25.99 Million DKK	30.596%
Zealand Pharma A/S	-249.03 Million DKK	107.243%